November 28, 2024

The FDA re­ject­ed Ap­plied Ther­a­peu­tics’ ex­per­i­men­tal treat­ment for a rare dis­ease called clas­sic galac­tosemia, cit­ing de­fi­cien­cies with the ap­pli­ca­tion. The com­pa­ny, while “dis­ap­point­ed with the

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more. The FDA has Sign up to

No­var­tis is lay­ing off 139 em­ploy­ees in East Hanover, NJ, as the com­pa­ny shifts its com­mer­cial re­sources away from two “well-es­tab­lished” med­i­cines. The Sign up

Af­ter the FDA re­ject­ed Out­look Ther­a­peu­tics’ oph­thalmic for­mu­la­tion of be­va­cizum­ab last year, the ex­per­i­men­tal ther­a­py has now failed a late-stage study in pa­tients with a

Plus, news about Portage Biotech: Re­cur­sion’s lay­offs: Af­ter merg­ing with fel­low AI-dri­ven biotech Ex­sci­en­tia this fall, Re­cur­sion Phar­ma­ceu­ti­cals laid off less than … Sign up

Kro­nos Bio is let­ting go near­ly all its em­ploy­ees af­ter flash­ing red lights ear­li­er this month. As part of an 83% work­force down­siz­ing, CEO Nor­bert

PTC Ther­a­peu­tics is stay­ing busy ahead of the Thanks­giv­ing hol­i­day. On Tues­day af­ter­noon, the com­pa­ny an­nounced that a Phase 2 tri­al eval­u­at­ing its ex­per­i­men­tal ALS